LIMIT is an immunogenic lncRNA in cancer immunity targetable for cancer immunotherapy [19], while NKILA, another lncRNA, can promote tumor immune evasion by sensitizing T cells and activate induced cell death [20]. This evidence concerns the gene NKILA and cancer.